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Aim: 
 
The aim of this study was to evaluate the Combination therapeutic  
potential of Gymnema sylvestre and Pergularia daemia on Estrodiol Valerate 
induced Polycystic Ovary Syndrome in Wistar Rats. 
Materials and Methods: 
 
In this study was PCOS treatment Gymnema sylvestre, Pergularia daemia 
and its combinations of plant powder against estradiol valerate induced rats. 12 
weeks aged thirty Female Wistar albino rats (180-230gm) were divided in to five 
groups of six animals per each. Treatment were designed as Group - I Normal 
Control, Group II Esradiol valerate (4mg/kg/i.p.) alone, Group III Gymnema 
Sylvestre (400mg/kg/orally) + Esradiol valerate (4mg/kg/i.p.), Group IV Pergularia 
daemia (250 mg/kg/orally) + Esradiol valerate (4mg/kg/i.p.), Group V Esradiol 
valerate (4mg/kg/i.p.) + Gymnema Sylvestre (400 mg/kg/orally) + Pergularia 
daemia (250 mg/kg/orally) (EV+GS+PD). The potency of Gymnema sylvestre, 
Pergualria daemia treatment against Estradiol Valerate induce PCOS was 
examine by following parameters biochemical, hormonal analysis, scan analysis 
and histopathological study of ovaries. 
Results: 
 
Estradiol Valerate induced groups of animals exhibited significant 
increased in serum Blood Glucose, Total cholesterol, Triglycerides, Body weight. 
The number of cystic and artretic follicles were higher in the EV-treatment group 
compared with the Normal control and Hormonal analysis significantly increased 
in LH, Estrogen, Testosterone and decreases the Progesterone & FSH level, 
which were reversed to normal levels in the treatment plant powder of Gymnema 
sylvestre, Pergularia daemia and its combinations. 
Conclusion: 
 
The present work was concluded the individual administration of 
G.sylvestre reduce the insulin resistance, decrease androgen production and 
P.daemia have profound beneficial effect on anovulation and menstrual 
irregularity. But the combination of G.sylvestre+P.daemia has potent synergistic 
activity to correct the hyperinsulinemia, anovuation and hyperandrogenism 
associated with PCOS. Further Isolation of active constituents and scope full 
clinical studies data are needed to initiate these combination for the better 
treatment and management of PCOS. 
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Chapter-1 
Introduction 
CHAPTER-1 
 
INTRODUCTION 
Polycystic ovary syndrome (PCOS) is one of the most common endocrinal 
disorders in women, among that 4-12% of women affecting at the reproductive 
age. It was first described by stein and Leventhal in 1935 and hence it also known 
as Stein Leventhal syndrome [1]. The reproductive features of PCOS include the 
increased production of androgen and disordered gonadotropin secretion leading 
to the menstrual irregularity, hirsutism, and infertility [2]. PCOS is characterized by 
hyperandrogenism, elevated androgen levels, acne, acanthosis nigricans, insulin 
insensitivity, and chronic anovulation [3]. Long term consequences lead to cancer, 
type-II diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disorder. 
The reproductive and metabolic features of PCOS are sometimes reversible with 
lifestyle modifications such as weight loss and lack of exercises. The etiology of 
PCOS is not clearly understood, but lipid imbalance, oxidative stress, insulin 
resistance and genetics are some of the contributing factors [4]. 
The pathophysiology of PCOS involves primary defects in the 
hypothalamic–pituitary axis, insulin secretion and ovarian function. It has been 
associated with insulin resistance and obesity [5]. The association with insulin 
resistance leads to increased production of androgen in theca cell by in the level 
of leutinizing hormome was increased and also the inhibition of hepatic synthesis 
of SHBG synthesis in liver cell. It prevents the normal follicular development in 
granulose cell by decrease in the level of follicular stimulating hormones which 
leads to follicular arrest. 
Different procedures have been developed to produce PCOS model 
including prenatal or pre-pubertal androgen exposure, aromatase inhibitor or 
estradiol administration, Testosterone Propionate (TP), Antiprogestin RU486 and 
Transgenic models. Exposure to a single dose of Estradiol Valerate (EV) in adult 
rat can cause irregular cycles, lack of ovulation and polycystic ovaries with high 
number of atretic follicles and cysts [6, 7]. In the present study were aimed to 
develop PCOS model through the EV-treated Rat. 
Various treatment modalities have been employed to manage PCOS. This 
can be treated with medications such as clomiphene citrate (CC) is a 
triphenylethylene derivative that is commonly used to induce ovulation in women 
[8] and also used for the PCOS treatment. The various drugs including tamoxifen, 
aromatase inhibitors, metformin, glucocorticoids and surgically by laparoscopic 
ovarian drilling [9]. However, therapeutic approaches to PCOS remain an ongoing 
source of debate. 
Many plants like Asparagus Racemosus, Grifola frondosa, Lepidium 
meyenii, Tinospora Cordifolia, Curcuma longa etc., have been highly esteemed 
sources which have the advantages to reduce PCOS and also having 
hypoglycaemic and anti-obesity effect. Nowadays some of the familiar medicinal 
plants and their bioactive extracts which plays a crucial role in treatment or 
prophylaxis of PCOS are summarized. It is concluded that the easily available 
beneficial herbs along with the lifestyle management is much effective in the 
prevention of PCOS than allopathic treatments [10]. 
Gymnema sylvestre (Asclepiadaceae) commonly known as “Gudmar” is a 
large woody, much branched climber with pubescent young parts in dry forest up 
to 600 mts height. Gymnema sylvestre leaves have been widely used in 
Ayurvedic traditional medicine. Leaves of the plant are used as antidiabetic, 
antiinflammatory, antiarthritic antiobesity, woundhealing astringent, bitter, acrid, 
thermogenic anodyne, digestive and liver tonic. Tannins, flavonoids and saponins 
are the chief Gymnemic acid chemical constituents present in Gymnema 
sylvestre. This plant possesses many more bioactive properties such as 
antimicrobial, larvicidal, antiviral, hypolipidemic, anticancer, antioxidant activity [11]. 
Gymnema also indicates the treatment of PCOS, due to its insulin modulating 
activity and the added benefits of reducing the elevated triglycerides associated 
with PCOS [12]. 
Pergularia daemia (Asclepiadaceae) known as “Uttaravaruni” in Sanskrit, is 
a perennial herb growing widely along the roadsides of India. Traditionally, the 
plant is useful as an anthelmintic, laxative, anti-pyretic, expectorant, and used in 
infantile diarrhea, Phytochemically the plant has been investigated for 
cardenolides, alkaloids, triterpenes and saponins. The plant has been 
documented for anti-inflammatory, anti-pyretic and analgesic activities, antifertility, 
antidiabetic, wound healing, antibacterial, and hepatoprotective activity [13]. It has 
potential effect on normalizing menstrual irregularities and regularizing the  
estrous cycle. So the restoration of the estrous cycle reduces the development of 
follicular cyst and regained normal level of LH and FSH upon the supplementation 
of Pergularia deamia [14]. 
Hence the individual administration of Gymnema sylvestre increase the 
insulin sensitivity and decrease insulin resistance and also decreases the 
androgen production, administration of Pergularia daemia regulates the irregular 
estrous cycle and hormonal levels and also it decreases the follicular cyst 
development. Hence this study was aimed to evaluate the combination 
therapeutic potential of Gymnema sylvestre and Pergularia daemia on Estradiol 
Valerate (EV) induced Polycystic Ovary Syndrome in rats. 
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2.1. Polycystic Ovary Syndrome 
 
 
Polycystic ovary syndrome (PCOS) is one of the most common endrocrine 
disorder frequently characterised by the accumulation of numerous cysts (fluid- 
filled sacs) on the ovaries associated with high male hormone levels 
(hyperandrogenism), ovulatory dysfunction, abdominal obesity, and other 
metabolic disturbances [15]. Initially called the Stein and Leventhal syndrome after 
its discovery in the 1935s, the term also deals with the multisystem involvement 
including hyperinsulinism, hyperlipididaemia, increased androgens, endometrial 
hyperplasia, diabetes mellitus, obesity, anovulation, cardiac disease and infertility 
[16]. 
 
2.1.1. TWO MAIN TYPES OF PCOS 
 
2.1.1.1. Insulin-Resistant PCOS 
 
Insulin-Resistant PCOS is also referred to as Type 1 PCOS, and it is most 
often associated with the classic symptoms of PCOS. These include weight gain, 
ovulatory interruptions, facial hair, hair loss and acne. Those with Insulin- 
Resistant PCOS also exhibit a greater potential for developing diabetes and 
increased testosterone levels both of which are actually caused by the underlying 
insulin resistance. Insulin resistance alters the hypothalamic pituitary ovarian axis 
leads to stimulation of theca cell to produce the excess amount of androgen and 
reduce in the level of SHBG synthesis in liver cells resulting hyperandrogenism 
and anovulation leads to polycystic ovarian syndrome. 
 
 
 
Figure No.1: Insulin Resistant Polycystic ovary syndrome 
 
 
2.1.1.2. Non-Insulin Resistant PCOS 
 
 
In this type of PCOS caused by Vitamin D or Iodine deficiency, hormone- 
disrupting toxins, thyroid disease, and adrenal stress. For women experiencing 
Non-Insulin Resistant PCOS, anti-Diabetic drugs will have no effect on the 
condition, and neither will help in reducing the weight which is gained due to 
hormonal imbalance. The treatment options in this case contribute to be more 
natural. Patients may be influenced to avoid dairy while also being prescribed 
supplements such as Iodine, Vitamin D, Magnesium, and Zinc, along with herbal 
formulas to reduce testosterone. Natural progesterone may also be prescribed in 
order to improve the hormonal imbalance and induce ovulation [17]. 
2.2. EPIDIMIOLOGY OF PCOS: 
 
 
In the United States, polycystic ovarian syndrome (PCOS) is one of the 
most common endocrine disorders of reproductive-age women, with a prevalence 
of 4-12%. Up to 10% of women are diagnosed with PCOS during gynecologic 
visits. In some European studies, the prevalence of PCOS has been reported to 
be 6.5-8%. 
 
A great deal of ethnic variability in hirsutism is observed. For example, 
Asian (East and Southeast Asia) women have less hirsutism than white women 
given the same serum androgen values. In a study that assessed hirsutism in 
southern Chinese women, investigators found a prevalence of 10.5%. In hirsute 
women, there was a significant increase in the incidence of acne, menstrual 
irregularities, polycystic ovaries, and acanthosis nigricans. 
 
PCOS affects premenopausal women, and the age of onset is most often 
perimenarchal (before bone age reaches 16 y). However, clinical recognition of 
the syndrome may be delayed by failure of the patient to become concerned by 
irregular menses, hirsutism, or other symptoms or by the overlap of PCOS 
findings with normal physiologic maturation during the 2 years after menarche. In 
lean women with a genetic predisposition to PCOS, the syndrome may be 
unmasked when they subsequently gain weight. 
 
The prevalence of hirsutism, acne, female pattern hair loss, acanthosis 
nigricans, seborrhea, striae, and acrochordons was found to be 78%, 48%, 31%, 
30%, 29%, 13%, and 9%, respectively [18]. 
 
 
 
Fig No. 2: Prevalence of cutaneous manifestations of PCOS patients 
 
 
2.3. PATHOGENESIS AND RISK FACTORS OF PCOS [19] 
 
2.3.1. Genetics: PCOS is believed to be a complex disorder, with genetic as well 
as environmental factors contributing to development of the disease. 20-40% of 
female first-degree relatives of women with PCOS also have the syndrome, 
suggesting that the disease is partially heritable and clusters in families. 
Prevalence and severity of presentation vary with ethnicity, with South Asians at a 
higher risk of disease. Some candidate genes have been identified as contributing 
to risk of the disease, including 7β-hydroxysteroid-dehydrogenase type 6 
(HSD17B6). 
 
2.3.2. Intrauterine exposures: exposures to testosterone in utero may 
predispose to the later development of PCOS. Animal studies have demonstrated 
that in utero exposure is correlated with development of a PCOS-like syndrome 
including hyperinsulinemia, hyperandrogenism, oligoanovulation, and polycystic 
ovaries. Exposure to androgens may impair estrogen and progesterone inhibition 
of GnRH, contributing to increased pulse frequency. 
2.3.3. Environment/lifestyle: several lifestyle factors and environmental 
exposures have been associated with a more severe PCOS phenotype. 
Sedentary lifestyle is associated with increased metabolic dysfunction, and weight 
gain is associated with oligoanovulation and hyperandrogenism. BPA and other 
environmental androgen-disrupting chemicals may accumulate to a greater extent 
in individuals with PCOS because of decreased hepatic clearance; these also 
induce androgen production and insulin resistance. 
 
 
 
Figure No.3: Pathogenesis of Polycystic Ovary Syndrome 
 
 
2.3.4. Obesity: although obesity is not believed to cause PCOS, it is known to 
exacerbate the symptoms of the disease. Obesity is present in 30-75% of women 
with PCOS. Adipose dysfunction contributes to the development of glucose 
intolerance and hyperinsulinemia, which in turn can exaggerate the 
manifestations of hyperandrogenisms. Obese women with PCOS are at increased 
risk of anovulation and consequent sub fertility. 
 
2.4. DIFFERENCE BETWEEN NORMAL MENSTURAL CYCLE AND 
POLYCYSTIC OVARIAN SYNDROME MENSTRUAL CYCLE 
 
2.4.1. Normal Menstrual Cycles 
 
 
The menstrual cycle starts when the brain sends LH and FSH to the 
ovaries. A big surge of LH is the signal that causes the ovaries to ovulate, or 
release an egg. The egg travales down the fallopian tube and into the uterus. 
Progesterone from the ovary causes the lining of the uterus to thicken. If the egg 
isn’t fertilized the lining of the uterus is shed. This is a menstrual period. After the 
menstrual period, the cycle begins all over again. The diagram right side shows a 
regular menstrual cycle, and the diagram on the left side shows a PCOS cycle 
with no ovulation. 
 
 
 
 
 
Figure No.4: Difference between Normal Menstrual Cycle and PCOS 
Menstrual Cycle 
 
2.4.2. Menstrual cycle in PCOS 
 
 
In women with polycystic ovary syndrome (PCOS), multiple small follicles 
(small cysts 4 to 9 mm in dm) accumulate in the ovary, hence the term polycystic 
ovaries. None of these small follicles are capable of growing to a size that would 
trigger ovulation. As a result, the levels of estrogen, progesterone, LH, and FSH 
become imbalanced. Androgens are normally produced by the ovaries and the 
adrenal glands. Examples of androgens include testosterone, androstenedione, 
dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEAS). Androgens may 
become increased in women with PCOS because of the high levels of LH but also 
because of high levels of insulin that are usually seen with PCOS [20]. 
 
2.5. PCOS AETIOLOGY 
 
 
2.5.1. Insulin Resistance 
 
 
Insulin is a hormone produced by the pancreas to control the amount of 
sugar in the blood. It helps to move glucose from blood into cells, where it's 
broken down to produce energy. Insulin resistance means the body's tissues are 
resistant to the effects of insulin. High levels of insulin cause the ovaries to 
produce too much testosterone, which interferes with the development of the 
follicles and prevents normal ovulation. Insulin resistance can also lead to weight 
gain. Insulin resistance is a pathophysiological contributor in around 50% to 80% 
of women with PCOS, especially in overweight women. Conversely, lean women 
and women with milder PCOS appear to have less severe hyperinsulinaemia and 
insulin resistance. Insulin resistance contributes to metabolic features but also to 
reproductive features through augmenting androgen production and increasing 
free androgens by reducing sex hormone binding globulin (SHBG) [21]. 
 
 
Figure No.5: Schema of aetiology and features of PCOS 
 
 
2.5.2. Hormone imbalance 
 
 
Many women with PCOS are found to have an imbalance in certain 
hormones. It includes. 
 
 Raised levels of Testosterone (T) – a hormone often thought of as a male 
hormone, although all women usually produce small amounts of it. 
 Raised levels of Luteinizing hormone (LH) – this stimulates ovulation, but 
may have an abnormal effect on the ovaries if levels are too high. Low 
levels of Sex hormone-binding globulin (SHBG) – a protein in the blood, 
which binds to testosterone and reduces its effect. 
 Raised levels of Prolactin– hormone that stimulates the breast glands to 
produce milk in pregnancy (only in some women with PCOS) 
 
2.5.3. Genetics 
 
 
PCOS is a multi-factorial disease sometimes runs in families. If any 
relatives, such as your mother, sister or aunt, have PCOS, then the risk of 
developing it is often increased. This suggests there may be a genetic link to 
PCOS, although specific genes associated with the condition are still under 
research. The several genes proposed and investigated as the main and possibly 
PCOS-related genes include those that regulate the HPO axis and those 
associated with peripheral insulin resistance and its sequelae. Genetic and 
environmental contributors to hormonal disturbances combine with other factors, 
including obesity, ovarian dysfunction and hypothalamic pituitary abnormalities to 
contribute to the aetiology of PCOS [22]. 
 
2.6. CLINICAL FEATURES OF PCOS [23] 
 
Women with PCOS may present with a variety of clinical upshots including 
 
 
 Reproductive manifestations like Menstrual irregularaties, Hirsutism, 
Infertility and Pregnancy complications 
 Metabolic implications like Insulin resistance, Obesity, Metabolic 
syndrome, IGT, DM2 and Potentially CVD 
 Psychological problems include reduced quality of life, poor self-esteem, 
depression, anxiety etc. (Table.1 & Figure.8) are shows the clinical 
manifestations of PCOS. 
 
Features of PCOS may manifest at any age, ranging from childhood 
(premature puberty), teenage (Hirsutism, Menstrual irregularities), early adulthood 
and middle life (infertility, Glucose intolerance) in later life (Diabetes Mellitus and 
Cardiovascular disease). 
 
 
Table No.: 1 Clinical manifestations and associated conditions 
 
 
2.6.1. Reproductive Manifestations of PCOS 
 
 
2.6.1.1. Ovarian dysfunction 
 
 
Ovarian dysfunction usually manifests as oligomenorrhoea/amenorrhoea 
resulting from chronic oligo-ovulation/anovulation. However, prolonged 
anovulation can lead to dysfunctional uterine bleeding which may mimic more 
regular menstrual cycles. The majority of PCOS patients have ovarian 
dysfunction, with 70% to 80% of women with PCOS presenting with 
oligomenorrhoea or amenorrhoea. Oligomenorrhoea occurs usually in 
adolescence, with onset later in life often associated with weight gain. 
Menorrhagia can occur with unopposed oestrogen and endometrial hyperplasia, 
further exacerbated by elevated oestrogen levels in obesity. 
 
2.6.1.2. Infertility 
 
 
It is the most common cause of anovulatory infertility. It accounts for 90% 
to 95% of women attending infertility clinics with anovulation. However 60% of 
women with PCOS are fertile, although time to conceive is often increased. 
Obesity independently exacerbates infertility, and induces a greater risk of 
miscarriage. 
 
2.6.1.3. Hyperandrogenism 
 
 
The clinical and biochemical signs of androgen excess in PCOS result  
from increased synthesis and release of ovarian androgens. Clinical 
hyperandrogenism primarily includes Hirsutism, Acne & seborrhea and Male 
pattern alopecia. 
 
2.6.1.3.1. Hirsutism 
 
 
PCOS is a common cause of hirsutism occurring in approximately 60% of 
cases; however this varies with race and degree of obesity. Hirsutism is defined 
as the presence of excessive terminal hair in areas of the body that are androgen- 
dependent and usually hairless or with limited hair growth, such as the face, 
upper lip, chin chest, abdomen, back, areolas, thighs and arms. It refers to a male 
pattern of body hair (androgenic hair).Normally, in females after pubarche the 
major androgenic molecules are Dehydroepiandrosterone sulfate (DHEAS), 
Androstenedione, Dehydroepiandrostenedione, Testosterone, and 
Dihydrotestosterone (DHT), in descending order of serum concentration. Only the 
Testosterone and DHT can bind to the androgen receptor and promote  hair 
follicle changes. Terminal hair should be differentiated from vellus hair. Terminal 
hair development requires androgen stimulation—as seen in pubarche, where 
androgens trigger vellus to mature into terminal hair and thus, hirsutism can be 
seen as the result of the interaction hyperandrogenemia and its influence in the 
hair follicle unit. 
 
 
Figure No.6: Clinical manifestations of PCOS 
2.6.1.3.2. Acne and Seborrhea 
 
 
Acne affects one third of cases and is not particularly specific for PCOS. 
Sebaceous glands are also androgen-dependent structures, with sebocytes being 
highly sensitive to androgen signalling, which is exacerbated in PCOS, leading to 
the development of acne, oily skin and seborrhea. Androgens stimulate sebocyte 
proliferation—especially in the mid-back, forehead, and chin and secretion of 
sebum. Local bacteria further complicate the process by secreting lypolytic 
enzymes which break down triglycerides produced in the sebocyte. 
 
2.6.1.3.3. Male pattern Hair loss (Androgenic alopecia) 
 
 
Hair is miniaturized, due to an increased telogen (the resting phase of the 
hair growth): anagen (anagen active growth phase of hair follicles) ratio with 
telogen hair being at mitotical rest and anagen hair being mitotically active and 
associated to genetic susceptibility related to increased 5a -reductase activity in 
the hair follicle. This increased enzymatic activity would favor the local conversion 
of testosterone into DHT, a more powerful androgen. The balding pattern is 
dominated by the frontal and parietal scalp zones, leaving the occipital area with 
great hair density, as opposed to thinner and scarcer hair in the crown area. 
 
2.6.1.3.4. Acanthosis Nigricans: 
 
 
Acanthosis nigricans, a dark and hyperpigmented hyperplasia of the skin 
typically found at the nape of the neck, axilla, groins is a marker for insulin 
resistance. Many adolescents with PCOS have higher levels of insulin in their 
blood, excess circulating androgens leads to dark patches. 
Other features of hyperandrogenism include virilisation, which, especially if 
presenting with clitoromegaly and rapid onset, requires exclusion of other causes 
including adrenal or ovarian androgen-secreting tumours. 
 
2.6.2. Metabolic Manifestations of PCOS 
 
 
2.6.2.1. Obesity 
 
 
It is a key magnifying factor of PCOS. It may play a pathogenetic role in the 
development of the syndrome in susceptible individuals. In fact, insulin possesses 
true gonadotrophic function and increased insulin availability at the level of 
ovarian tissue may favour excess androgen synthesis. Obesity, particularly the 
abdominal phenotype, may be partly responsible for insulin resistance and 
associated hyperinsulinemia in women with PCOS. Therefore, obesity-related 
hyperinsulinemia may play a key role in favouring hyperandrogenism in these 
women. Irrespective of the pathogenetic mechanism involved, obese PCOS 
women have more severe hyperandrogenism and related clinical features than 
normal-weight PCOS women. 
 
2.6.2.2. Dyslipidaemia 
 
 
Dyslipidaemia is common in PCOS compared to weight matched controls, 
with higher triglycerides and lower high density lipoprotein cholesterol. It occurs 
independent of body mass index, however there is a synergistic deleterious effect 
of obesity and insulin resistance in PCOS analogous to that seen in DM2. The 
causes of dyslipidaemia in PCOS are again multifactorial. Insulin resistance 
appears to have a pivotal role mediated in part by stimulation of lipolysis and 
altered expression of lipoprotein lipase and hepatic lipase. 
2.6.2.3. Insulin resistance and abnormal glucose metabolism 
 
 
Insulin resistance occurs in around 50% to 80% of women with PCOS. 
Primarily in the more severe NIH diagnosed PCOS and in those who are 
overweight. Lean women and milder Rotterdam diagnosed PCOS appear to have 
less severe insulin resistance. It results in hyperinsulinaemia with its associated 
diverse and complex effects on regulating lipid metabolism, protein synthesis and 
modulation of androgen production. Women with PCOS are at increased risk of 
developing IGT and DM2 with prevalence rates of 31.3% and 7.5%, respectively. 
Also develop abnormal glucose metabolism at a younger age and may 
demonstrate a more rapid conversion from IGT to DM2 
 
2.6.2.4. Cardiovascular disease risk 
 
 
Alongside insulin resistance, metabolic syndrome, IGT and DM2, women 
with PCOS also have increased novel cardiovascular risk factors (inflammation, 
oxidative stress and impaired fibrinolysis) 
 
2.6.3. Psychological Manifestation of PCOS 
 
 
The challenges to familiarly identity and body image due to obesity, acne 
and excess hair, as well infertility and long-term health-related concerns 
compromise quality of life and adversely impact on mood and psychological well- 
being. PCOS women are more prone to depression, anxiety, low self-esteem, 
negative body image, and psychosexual dysfunction. 
 
The other critical aspect of psychosocial impact in PCOS is the negative 
impact of mood disturbance, poor self-esteem and reduced psychological well- 
being on motivation and on ability to implement and sustain successful lifestyle 
changes that are critical in this condition. These issues all need to be explored 
and addressed as part of PCOS assessment and management. 
 
2.7. DIAGNOSTIC CRITERIA FOR PCOS 
 
 
PCOS has undergone multiple sequences of Diagnostic criteria. Since 
1990, various bodies have laid down criteria for the diagnosis of PCOS, based on 
oligo or anovulation, signs of hyperandrogenism, and ovarian sonography. Many 
definitions are used for diagnosis of PCOS such as National Institutes of Health 
(NIH) criteria, Rotterdam criteria and Androgen Excess PCOS Society criteria. 
 
 
Table No.: 2 Diagnosistic criteria for PCOS 
 
 
2.7.1. NIH criteria: In 1990, a workshop sponsored by the NIH suggested that a 
patient has PCOS if she has oligo ovulation, signs of androgen excess (clinical or 
biochemical) and other entities are excluded that would cause polycystic ovaries. 
 
2.7.2. Rotterdam criteria: In 2003, a consensus workshop held in Rotterdam 
indicated PCOS to be present if any 2 out of 3 criteria are met including 
oligoovulation and/or anovulation, excess androgen activity and polycystic ovaries 
(By gynecologic ultrasound).The Rotterdam definition is wider, including many 
more patients, most notably patients without androgen excess. Critics say that 
findings obtained from the study of patients with androgen excess cannot 
necessarily be extrapolated to patients without androgen excess. 
 
2.7.3. Androgen excess PCOS Society criteria: In 2006, the Androgen Excess 
PCOS Society suggested a tightening of the diagnostic criteria to all of the 
following including excess androgen activity, oligo ovulation/anovulation, 
polycystic ovaries and other entities are excluded that would cause excess 
androgen activity [24] [25]. 
2.8. TREATMENT OF POLYCYSTIC OVARY SYNDROME 
 
2.8.1. Therapies aimed at treating Anovulatory Infertility 
 
The recommended first line treatment for ovulation induction remains the 
antiestrogen clomiphene citrate (CC). Recommended second line intervention is 
either exogenous gonadotropins or laparoscopic ovarian surgery [29].There 
appears to be some benefit of addition of metformin to clomiphene, especially in 
obese subjects (modified first line treatment). 
2.8.1.1. Clomiphene citrate 
 
It is a triphenylethylene derived nonsteroidal agent that is theorized to 
function at the level of the hypothalamus as an anti estrogen to improve 
gonadotropin secretion. An important concern is the relatively high rate of multiple 
pregnancies (7.8%) after conception, majority being twins [26]. 
2.8.1.2. Gonadotropins 
 
These are frequently used to induce ovulation in women with PCOS for 
whom clomiphene treatment has failed. Low dose therapy with gonadotropins 
offers a higher rate of ovulation, monofollicular development, with a significantly 
lower risk of ovarian hyperstimulation syndrome [25]. 
2.8.1.3. Ovarian surgery 
 
This is primarily recommended as second line infertility therapy. Multiple 
pregnancy rates are reduced in those women who conceive following 
laparoscopic drilling. In some cases, the fertility benefits of ovarian drilling may be 
temporary and adjuvant therapy after drilling with clomiphene may be necessary. 
Ovarian drilling does not appear to improve metabolic abnormalities in women 
with PCOS [27] 
2.8.1.4. Aromatase inhibitors 
 
Aromatase inhibitors such as letrozole and anastrazole have been 
proposed as both first and secondary treatment for ovulation induction (in women 
with PCOS and also for unexplained infertility. Results in women with PCOS 
appear comparable to clomiphene from small trials. Proposed benefits include 
oral administration, a shorter half life than clomiphene, more favorable effects on 
the endometrium, potentially higher implantation rates, and lower multiple 
pregnancy rates due to monofollicular ovulation. Their use is still experimental at 
this point [28]. 
2.8.1.5. Thiazolidinediones 
 
Smaller trials have shown some benefit to this class of drugs for the 
treatment of infertility usually in conjunction with clomiphene [29]. However the 
concern about hepatotoxicity, cardiovascular risk, weight gain, and the pregnancy 
Category C have limited the use of these drugs in women with PCOS. 
2.8.2. Therapies aimed at improving Insulin sensitivity to treat anovulation 
and Androgen excess 
A logical approach to the management of PCOS includes using life style 
measures and medications that improve insulin sensitivity in target tissues, 
achieving reductions in insulin secretion, and stabilizing glucose tolerance. 
2.8.2.1. Lifestyle modification 
 
The gold standard for improving insulin sensitivity in obese PCOS women 
should be weight loss, diet, exercise. It is recommended as the first line of 
treatment in obese women who present with infertility. Hypo-caloric diets result in 
appropriate weight loss in women with PCOS. Unfortunately, there have been few 
studies on the effect of exercise alone on symptoms in PCOS women; although it 
is reasonable to assume that exercise would have the same beneficial effects in 
women with PCOS as it does in women with type 2 DM. However the exercise 
program must be tailored to the degree of obesity, and the patient’s baseline 
fitness [30] [31]. 
2.8.2.2. Biguanide 
 
Metformin may be most useful in the long term maintenance of PCOS. 
Metformin does lower serum androgens, and improves ovulatory and menstrual 
frequency. Metformin is the drug of choice to treat glucose intolerance and 
elevated diabetes risk in women with PCOS. Its use throughout pregnancy has 
shown to have beneficial effects in reducing early pregnancy loss and have a 
favorable effect on plasma glucose levels and other metabolic aspects [37]. 
Metformin is also associated with weight loss in women with PCOS, although the 
results in other populations are inconsistent. The dose is usually 1500-2000 
mg/day given in divided doses. Metformin carries a small risk of lactic acidosis, 
most commonly among women with poorly controlled diabetes and impaired renal 
function. Other reported side effects include vitamin B12 deficiency, peripheral 
neuropathy [32]. 
2.8.2.3. Thiazolidinediones 
 
Pioglitazone and rosiglitazone are pharmacological ligands for the nuclear 
receptor peroxisome proliferator activated receptor (PPAR). They improve the 
action of insulin in the liver, skeletal muscles, adipose tissue and have only 
modest effect on hepatic glucose output. Improving insulin sensitivity with these 
drugs is associated with a decrease in circulating androgen levels, improved 
ovulation rate, and improved glucose tolerance. However the concern about 
hepatotoxicity, cardiovascular risk, weight gain, and the pregnancy category C 
have limited the use of these drugs in women with PCOS [33]. 
2.8.3. Therapies aimed at Treating Oligomenorrhea 
 
If the patient does not wish to conceive, medical therapy is directed 
towards interruption of the effect of unopposed estrogen on the endometrium. 
Nonfluctuating levels of unopposed estradiol in the absence of progesterone 
cause irregular uterine bleeding, amenorrhea, infertility and increased risk of 
endometrial cancer. 
2.8.3.1. Combination of oral contraceptives 
 
Oral contraceptives have been the mainstay of long term management of 
PCOS. They offer benefit through a variety of mechanisms, including suppression 
of pituitary LH secretion, suppression of ovarian androgen secretion, and 
increased circulating SHBG levels. Individual OC preparations may have different 
doses and drug combinations and thus have varying risk–benefit ratios. Most oral 
contraceptives (OC) preparations contain estrogen (ethinyl estradiol 0.030 mg) in 
combination with antiandrogens. Anti androgens include cyproterone acetate, 
drosperinone, levonorgestril, norgestimate and desogestril. The “best” oral 
contraceptive for women with PCOS is unknown. A low dose oral contraceptive 
pill is therefore recommended. 
Oral contraceptives may also be associated with a significant elevation in 
circulating triglycerides as well as in high density lipoprotein (HDL) levels, though 
these do not appear to progress over time. There is no evidence to suggest that 
women with PCOS experience more cardiovascular events than the general 
population when they use oral contraceptives. If a woman is taking an oral 
contraceptive that contains drospirenone, a progestin with antimineralocorticoid 
properties, it may be necessary to reduce her dose of spironolactone if used 
concomitantly. Regular evaluation of potassium levels is necessary [34]. 
2.8.3.2. Progestin 
 
Both depot and intermittent oral medroxyprogesterone acetate (10 mg for 
10 days) have been shown to suppress pituitary gonadotropins and circulating 
androgens in women with PCOS. No studies have addressed the long term use of 
these compounds to treat hirsutism. There is also a paucity of data to address the 
varying risk benefit ratios of varying classes of progestins. Progestin only oral 
contraceptives are an alternative for endometrial protection, but they are 
associated with a high incidence of breakthrough bleeding [35]. 
2.8.4. Therapies aimed at Treating Hirsuitism 
 
No oral contraceptive has been approved by the FDA for the treatment of 
hirsutism. A number of observational or nonrandomized studies have noted 
improvement in hirsutism in women with PCOS who use oral contraceptives, but 
no studies of adequate power confirm their benefit in improving hirsutism  in 
PCOS [36] . 
2.8.4.1. Spironolactone 
 
It is primarily used to treat hirsutism and appears effective, though the 
evidence is weak. It is a diuretic and aldosterone antagonist, also binds to the 
androgen receptor as an antagonist. It has other mechanisms of action, including 
inhibition of ovarian and adrenal steroidogenesis, competition for androgen 
receptors in hair follicles, and direct inhibition of 5 alpha reductase activities. The 
usual dose is 25–100 mg twice a day, and is titrated to balance efficacy while 
avoiding side effects such as orthostatic hypotension. A full clinical effect may 
take 6 months or more. About 20% of women using spironolactone will 
experience increased menstrual frequency [37]. Because it can cause and 
exacerbate hyperkalemia, spironolactone should be used cautiously in women 
with renal impairment. Rarely, exposure has resulted in ambiguous genitalia in 
male infants. 
2.8.4.2. Cyproterone acetate 
 
It is a progestogen with anti androgen properties. It is frequently combined 
in an oral contraceptive tablets and is popular in the treatment of PCOS. A newer 
progestin from the same class, drospirenone has been marketed in the U.S. as 
especially effective for the treatment of female hyperandrogenism, although the 
data suggesting this is superior to other formulations is not based on head to 
head randomized trials [38]. When given as 100mg/day, it inhibits testosterone 
production resulting in upto 75% decrease in circulating testosterone levels. 
2.8.4.3. Flutamide 
 
It is an androgen receptor antagonist, and is another non steroidal 
antiandrogen that has been shown to be effective against hirsutism in smaller 
trials the most common side effect is dry skin, but its use has been associated 
with hepatitis in rare cases. The common dosage is 250 mg/day. The risk of 
teratogenicity with this compound is significant, and contraception should be 
used. Flutamide has also been combined with lifestyle and metformin therapy for 
treatment of PCOS and may have additive effects [39]. 
2.8.4.4. Finasteride 
 
It is a specific inhibitor of type II 5-reductase enzyme found in the hair 
follicles on the top of the scalp and in the sebaceous gland ducts. Its use is 
restricted to women in the post-menopausal group or women with documented 
hyperandrogenic state in the dosage of 5 mg/day. Finasteride is better tolerated 
than other antiandrogens, with minimal hepatic and renal toxicity; however, it has 
well documented risk for teratogenicity and feminising in a male fetuses, and 
adequate contraception should be used. Overall, randomized trials have found 
that spironolactone, flutamide and finasteride to have similar efficacy in improving 
hirsutism [40]. 
2.8.4.5. Ornithine decarboxylase inhibitors 
 
These have been developed for the treatment of female hirsutism. 
Ornithine decarboxylase is necessary for the production of polyamines, and 
inhibition of this enzyme limits cell division and function in the pilosebaceous unit. 
Recently a potent inhibitor of this enzyme, eflornithine, has been found to be 
effective as a facial cream for the treatment of unwanted facial hair. It is available 
as a 13.9% cream of eflornithine hydrochloride, and is applied to affected areas 
twice daily. 
In clinical trials, 32% of patients had marked improvement after 24 weeks 
compared to 8% of placebo treated women, and the benefit was first noted at 
eight weeks. It is pregnancy category C drug. It appears to be well tolerated, with 
only about 2% of patients developing skin irritation or other adverse reactions. 
Relapse is common after stopping [41]. 
2.8.5. Mechanical and Cosmetic Means of Hair Reduction and Destruction 
 
Mechanical hair removal techniques like shaving, plucking, waxing, 
depilatory creams, electrolysis, and laser hair reduction (LHR) offer good 
cosmetic relief and often are the front line of treatment used by women. A word of 
caution regarding facial waxing as it cans [42]. Precipitate folliculitis.  Various 
lasers are used for hair reduction and include the Diode (800nm), Alexandrite 
(755 nm).It results in reduction in density and thickness of hair but if at any point 
in time, there is uncontrolled androgen excess, there will be a relapse in  
hirsutism. 
2.8.6. Statins 
 
Another area where there is emerging support in the literature for a 
cardiovascular and endocrine benefit in women with PCOS is the use of statins. 
They have been shown to improve hyperandrogenemia, lipid levels, and reduce 
inflammation [43]. Statins may prove to be an additional therapeutic tool for the 
steroidogenic abnormalities in PCOS. However, available data are limited and 
should be interpreted with caution until further research has been carried out. A 
recent study among women receiving combined treatment of statin and OCP has 
shown a significant statin-attributable attenuation of clinical and biochemical 
hyperandrogenism in concert with amelioration of cardiovascular risk factors. This 
clinical study has provided support to previous in vitro findings showing that statin 
inhibits proliferation and steroidogenesis of ovarian theca-interstitial cells from 
PCOS women. Owing to the potential fetal toxicity of statins, effective 
contraception is essential when statin treatment is assigned in women of 
reproductive age. 
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PLANTS PROFILE 
 
3.1 GYMNEMA SYLVESTRE 
 
Botanical name : Gymnema sylvestre 
 
Family : Asclepiadaceae (Milk weed family) 
 
3.1.1 Vernacular names [44] 
 
Tamil : Shirukurum Kaay, Shakkaraikolli,Kokilam 
 
English : Periploca of the woods 
 
Hindi : Gudmar, Gurmar 
 
Sanskrit : Meshashringi, Madhunashini 
 
Malayalam : Chakkarakkolli 
 
Telugu : Podapatri 
 
Kannada : Sannagerasehambu, Kadhasige 
 
Marathi : Kavali, Kalikardori 
 
Gujarati : Dhuleti, Mardashingi 
 
Siddha : Kannu Minnayamkodi, Passaam, Shirukurinja 
 
Unani : Gurmaar Buuti 
 
3.1.2 Taxonomical name 
 
Kingdom : Plantae 
 
Subkingdom : Tracheobionta 
 
Division : Magnoliophyta 
 
Class : Magnoliopsida 
 
Subclass : Asteridae 
 
Order : Gentianales 
Family : Asclepiadaceae 
 
Genus : Gymnema 
 
Species : G.sylvestre 
 
 
3.1.3 Distribution of Gymnema sylvester 
 
 
 
Figure No.7: Aerial Parts of Gymnema Sylvester & Powder of Gymnema 
sylvester 
 
Woody, large climber running over tops of high trees; young branches 
slender and pubescent; leaves opposite, simple, petioles 0.6-1.2 cm, stout or 
slender, lamina 2.5-6.25 cm in length, elliptic or ovate, thinly coriaceous, upper 
surface rarely pubescent; cymes sub globose, ± 1.25 cm in diameter; flowers 
yellow, ±0.2 cm in diameter; follicles slender, ±5-7.5 by 0.8 cm; seeds pale brown, 
flat, along with thin broad marginal wing. Distributed in: Asia, tropical Africa and 
Australia [45]. 
3.1.4. Phytoconstituents of Gymnema sylvestre 
 
Plant constituents are flavones, anthraquinones, hentri-acontane, 
pentatriacontane, α and β-chlorophylls, phytin, resins, d-quercitol, tartaric acid, 
formic acid, butyric acid, lupeol, β-amyrin related glycosides, stigmasterol, 
gymnemic acids, tartaric acid, gurmarin, calcium oxalate, glucose, saponins, 
stigmasterol, quercitol. The plant extract also tests positive for alkaloids. Leaves 
of this species yield acidic glycosides and anthroquinones and their derivatives 
and the amino acid derivatives betaine, choline and trimethylamine [46]. 
 
3.1.5. Pharmacological action of Gymnema sylvestre: 
 
3.1.5.1. Antidiabetic Activity 
 
The herb accounts for its sweet inactivation property to the presence of 
triterpene saponins known as gymnemic acids, gymnemasaponins, and gurmarin. 
Experimental trials confirmed the hypoglycemic effect of G. sylvestre on beryllium 
nitrate and streptozotocin treated rats. There was a slight increase in body weight 
and protein and a significant decrease in fasting blood glucose in diabetic rats 
treated with G. sylvestre, C. auriculata, E. jambolanum, and S. reticulata and the 
effects were quite similar to insulin and glibenclamide treatment [47]. 
 
 
 
Figure No.8: Pharmacological action of Gymnema sylvestre 
 
3.1.5.2. Antiarthritic Activity 
 
The leaf extract of G. sylvestre was examined for antiarthritic activity on 
albino rats. The water soluble and petroleum ether (40–60°C) extract was found 
to be significantly effective in controlling arthritis. It was also assumed that the 
most potent antiarthritic activity of the leaves may be due to the nature of 
triterpenoids, steroids, and saponin glycosides [48]. 
 
3.1.5.3. Treatment of Dental Caries 
 
Dental caries can be defined as infection of tooth, occurring due to various 
kinds of gram-positive cariogenic bacteria like S. aureus, S. mitis, and S. mutans, 
and fungus-like Candida albicans which attaches to the tooth surface through 
release of extracellular polysaccharides from sucrose and metabolize sugar to 
organic acid mainly lactic acid resulting in demineralization of the tooth enamel [49]. 
The good potential of the hydroalcoholic extract of the plant leads to the 
development and manufacture of gurmar tooth powdered marketed as “Gurmar 
Herbal tooth paste” and “Gurmar Herbal Tooth powder.” These herbal 
formulations offer new prospects in the treatment of dental caries once clinically 
approved by the scientific community [50]. 
 
3.1.5.4. Antibiotic and Antimicrobial Activity 
 
The antibiotic and antimicrobial activity of different extracts of  G.  sylvestre 
 
was determined  against a number of pathogens, namely,  S. aureus, E. coli,  and 
 
B. subtilis while no activity was observed against gram-negative bacteria. G. 
sylvestre leaf extracts showed good prospects as an antibiotic herbal remedy was 
effective as herbal formulation for the treatment of microbe’s related infections. 
The antibacterial activity of G. sylvestre and gymnemic acid was also studied 
against E. coli and B. cereus and the antimicrobial effect was significant against 
the microbes [51]. 
 
3.1.5.5. Anti-Inflammatory Activity 
 
In the Ayurvedic system of medicine, the leaf of G. sylvestre has been 
widely used and is considered as bitter, acrid, thermogenic, digestive, liver tonic, 
anodyne, and anti-inflammatory. The bioactive constituents in G. sylvestre known 
as tannins and saponins are responsible for the anti-inflammatory activity of the 
plant [52]. 
 
3.1.5.6. Anticancer and Cytotoxic Activity 
 
Many plant-derived saponins, namely, ginsenosides, soyasaponins, and 
saikosaponins have been found to exhibit significant anticancer activity. 
Anticancer potential of gymnemagenol on HeLa cancer cell lines in in vitro 
conditions was determined. The cytotoxic activity of the saponins was tested by 
MTT cell proliferation assay. Different concentrations of gymnemagenol (5, 15, 
25, and 50 μg/mL) were taken and plates were incubated for 48 hours. The IC50 
value was found to be 37 μg/mL for gymnemagenol and after 96 hours, the  
extract at a concentration of 50 μg/mL showed good cytotoxic activity on 73% on 
HeLa cells. The isolated bioactive constituent, gymnemagenol, was found to show 
a high degree of inhibition to the proliferation of HeLa cancer cell line [53]. With the 
rising percentage of cancer in people, the herbal formulation is a prospective 
medication in cancer therapy. 
 
3.1.5.7. Antihyperlipidemic Activity 
 
The prevalence of coronary artery disease is the cause of higher incidence 
of mortality than other causes combined. The major factor contributing to 
atherosclerosis and related disorders like coronary artery diseases is 
hyperlipidemia. Reduction in serum cholesterol levels may significantly reduce the 
chances of coronary heart disease. Due to the limitations of synthetic drugs in 
having adverse effects, plant-based formulations offer a good prospect for the 
treatment of heart disease. Gymnemic acids preparations have been found to be 
effective against obesity [54]. 
 
3.1.5.8. Immunostimulatory Activity 
 
Immunomodulation is referred to as the regulation or control of the 
immunity which involves the enhancement or reduction in the immune responses. 
The body response to a particular condition might be regulated by agent that 
enhances or suppresses its action [55]. G. sylvestre is reported to be an 
immunostimulatory plant and the leaves possess immunostimulatory effect [53] the 
aqueous leaf extract was tested for immunostimulatory activities by detecting the 
movement of neutrophils, chemotaxis tests, phagocytosis of killed C. albicans, 
and nitroblue tetrazolium assays. Aqueous leaf extract of G. sylvestre showed 
remarkable immunostimulatory activity on human neutrophils under in vitro 
conditions [56]. 
 
3.1.5.9. Hepatoprotective Activity 
 
The hepatoprotective effect of hydro-alcoholic extract of G. sylvestre was 
evaluated. The rat hepatocytes (freshly prepared) were subject to treatment with 
different concentration of hydroalcoholic extract prepared by the hot maceration 
process. The G. sylvestre showed significant antihepatotoxicity against the D- 
galactosamine-induced hepatotoxicity, and the concentration was found to be 
cytotoxic. The cells exhibited a significant restoration of the altered biochemical 
parameters towards the normal when compared to D-galactosamine treated 
groups in a dose-dependent manner, when treated with the hydroalcoholic extract 
different extracts of G. sylvestre [57]. 
 
3.1.5.10 Wound Healing Activity 
 
The alcoholic extract of leaves of G. sylvestre was found to exhibit 
significant wound healing activity in rats. G. sylvestre has good wound healing 
property. TLC analysis, wound contraction, and qualitative tests supported the 
synergistic wound healing effect of the plant. The increased wound healing 
activity of hydroalcoholic extracts may be attributed to the free radical scavenging 
action and the presence of phytoconstituents (flavonoids) which may act 
individually or have additive effect [58]. 
3.2 PERGULARIA DAEMIA [59] 
 
Botanical name : Pergularia daemia 
 
Family : Asclepiadaceae 
 
3.2.1 Vernacular names 
 
Tamil : Uttamani, Veliparuthi, Beliparti, Nandamani, 
 
English : Hariknot plant 
 
Hindi : Utaran, sagovani, Aakasan, Gadaria Ki 
bel,Jutak 
Sanskrit : Uttamarani, Kurutakah, Visanika, Kakajangha 
 
Malayalam : Veliparatti 
 
Telugu : Dustapuchettu, Jittupaku, Gurtichettu 
 
Kannada : Halokoratige, Juttuve, Talavaranaballi 
 
Marathi : Utarn 
 
Gujarati : Chamardudhi 
 
Bengali : Chagalbati, Ajashringi 
 
3.2.2 Taxonomical name 
 
Kingdom : Plantae 
 
Subkingdom : Tracheobionta 
 
Subdivision : Spermatophyta 
 
Division : Magnoliophyta 
 
Class : Magnoliopsida 
 
Subclass : Asteridae 
 
Order : Gentianales 
 
Family : Asclepiadaceae 
Genus : Pergularia 
 
Species : P. daemia (Forsk) Chiv 
 
3.2.3 Distribution of Pergularia daemia 
 
 
 
Figure No.9: Aerial Parts of Pergularia daemia 
 
Pergularia daemia is a perennial twining herb, foul-smelling when bruised; 
Stems bears milky juice and covered with longer stiff erect hairs 1mm; Leaves are 
thin, broadly ovate and heart-shaped 2-12 cm long, covered with soft hairs; 
Greenish yellow or dull white, sweet-scented flowers born in axillary, double white 
corona at the base of a stamina column, long-peduncled, umbellate or corymbose 
clusters tinged with purple; Fruits paired with follicles 5.8 cm long and 1 cm in 
diameter, reflexed, beak long, covered with soft spinous outgrowth and release 
many seeds with long white hairs when they split open. Seeds are  densely 
velvety on both sides. The entire plant constitutes the drug and is used as a 
medicine [60]. 
3.2.4 Phytoconstituents of Pergularia daemia 
 
Most commonly found phytochemicals from the leaves of P. daemia are 
flavonoids alkaloids, terpenoids, tannins, steroids and carbohydrates. 
Phytochemical studies have shown the presence of cardenolides, alkaloids, 
triterpenes (lupeol), saponins, steroidal compounds. The seeds of P. daemia 
contain uzarigenin, coroglaucigenin, calactin, calotropin, other cardenolides and a 
bitter resin, Pergularin and have a cardiotoxic action. It has been suggested that 
the plant seed action on the uterus is similar to that of pituitrin and is not inhibited 
by progesterone [61]. 
3.2.5. Pharmacological action of Pergularia daemia 
 
Pharmacological activity of the Pergularia daemia such as Anti- 
inflammatory, analgesic and antipyretic activity, Anti diabetic activity, Anti fungal 
activity, Anti bacterial activity, Central nervous system depressant activity, 
Hepatoprotective activity, Anti oxidant activity, Anticancer activity [62]. 
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AIM AND OBJECTIVES 
 
Polycystic ovary syndrome is one of the most common endocrine 
metabolic disorders characterised by polycystic ovaries, chronic anovulation and 
hyperandrogenism leading to symptoms of menstrual irregularity, hyperinsulinimia 
and obesity. 
In current allopathy medication such as clomiphene citrate (CC),  
tamoxifen, aromatase inhibitors, metformin, glucocorticoids and surgically by 
laparoscopic ovarian drilling are may less effective for the polycystic ovarian 
syndrome and also it will produce the adverse effect and high cost. But, now a 
day’s Phytomedicines are effective for the Potential treatment of polycystic ovary 
syndrome. 
Many plants like Asparagus Racemosus, Grifola frondosa, Lepidium 
meyenii, Tinospora Cordifolia, Curcuma longa etc., have been highly esteemed 
sources which have the advantages to reduce PCOS and also having 
hypoglycaemic and anti-obesity effect. Nowadays some of the familiar medicinal 
plants and their bioactive extract which plays a crucial role in treatment of PCOS. 
The easily available beneficial herbs along with the lifestyle management are 
much effective in the prevention of PCOS than allopathic treatments. 
The treatment of herbal plants Gymnema sylvestre to increase the insulin 
sensitivity and decrease excess of insulin level, it increase the SHBG synthesis in 
liver cells leads to decreases in the level of androgen production. Pergularia 
daemia regulate the estrus cycle and hormonal levels and also it decreases the 
follicular cyst development. It is well known treatment of Polycystic Ovarian 
Syndrome in regularized pattern of estrus cycle. 
Hence objective of this study is to evaluate the Gymnema sylvestre and 
 
Pergularia daemia plants individual and combination effect on 
 
 Hyperinsulinemia
 
 Irregular mensutural cycle and
 
 Follicular cyst developments in estrodiol valerate induced PCOS in rats.
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PLAN OF STUDY 
 
1. Collection of Plant materials 
 
2. Pharmacological study design 
 
a) Selection of Animals 
 
b) Animal Grouping 
 
3. Induction of Polycystic Ovary Syndrome in rats 
 
4. Physical Evaluation 
 
a) Body weight 
 
b) Feed intake 
 
5. Examination of Vaginal smear 
 
6. Biochemical Estimation 
 
a) Estimation of Blood glucose 
 
b) Estimation of Total Cholesterol 
 
c) Estimation of Triglycerides 
 
d) Estimation of serum glutamic-oxaloacetic transaminase (SGOT) 
 
e) Estimation of serum glutamic pyruvic transaminase (SGPT) 
 
f) Estimation of Alkaline phosphatase ( ALP) 
 
g) Estimation of Urea 
 
h) Estimation of Creatinine 
 
7. Hormonal Determination 
 
a) Determination of LH 
 
b) Determination of FSH 
 
c) Determination of Total Testosterone 
 
d) Determination of Estrogens 
e) Determination of Progesterone 
 
8. Ultrasound Scan Analysis 
 
9. Measurement of Organs Weight 
 
10. Histopathological Examination 
 
11. Statistical Analysis 
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MATERIALS AND METHODS 
 
6.1. Drugs and chemicals 
 
All the chemicals and drugs used in this study were of analytical grade. 
 
The following chemicals were used for the experimental study. 
 
 
S.No. Material Source 
1. Estrodiol valerate Bayer Zydus Pharm Pvt. Ltd., Theane 
2. Gymnema sylvestre powder 
Genius Nature Herbs Pvt. Ltd. 
Coimbatore 
3. Pergularia daemia powder 
Genius Nature Herbs Pvt. Ltd. 
Coimbatore 
4. Methylen blue S.d fine chemicals Ltd. Mumbai 
5. Formic acid NICE chemicals Pvt. Ltd. India 
6. Diethyl ether LOBA Chemie Pvt. Ltd. Mumbai 
7. Choloroform LOBA Chemie Pvt. Ltd. Mumbai 
8. Biochemical diagnostic kit Thermo Fisher Scientific. India 
9. Enzyme immunoassay kit Thermo Fisher Scientific. India 
 
6.2. Pharmacological study Design 
 
6.2.1. Selection of Animals 
 
The colony inbred adult Female Albino Wistar Rats, weighing 180-230gm 
were obtained from Central Animal house of Swamy Vivekanandha College of 
Pharmacy, Elayampalayam, Namakkal – 637 205. The animals were kept under 
standard environmental conditions of 12/12 light/dark rhythm, maintained under 
controlled room temperature (23±2ºC) and a relative humanity of 60%±10% in 
polypropylene cages. They were fed with standard pellet diet and water ad 
libitum. Each cage contained 3 rats of the sex with a bedding of husk. The 
immature animals were acclimatized under laboratory conditions three days prior 
to initiation of the experiment. The cages were cleaned daily by changing the  
husk bedding. 
The experimental protocol was approved by the Institutional Animal Ethical 
Committee (IAEC) of Swamy Vivekanandha College of Pharmacy, 
Elayampalayam, Namakkal – 637 205. Care and use of laboratory animals were 
confirmed to CPCSEA guidelines. 
IAEC Reference No: SVCP/IAEC/PG/1/03/2017 dated 09.12.2016 
 
6.2.2. Animal grouping 
 
12 weeks aged thirty wistar female rats weighing 180-230 gm were 
randomly divided into five groups of six per each. The groups and treatment are 
designed as follows 
Group I: Control receives 0.4ml in Sesam oil i.p. + Distilled water p.o. 
 
Group II: PCOS control receives Estradiol valerate (4mg/kg in 0.4ml Sesam oil 
i.p.) 
Group III: Gymnema Sylvestre (400mg/kg/p.o.) + Estradiol valerate (4mg/kg in 
0.4ml Sesam oil i.p.). 
Group IV:  Pergularia daemia (200mg/kg/p.o) + Estradiol valerate (4mg/kg in 
0.4ml Sesam oil i.p.) 
Group V: Estradiol valerate (4mg/kg in 0.4ml Sesam oil i.p.)  +Gymnema 
Sylvestre (400mg/kg/p.o) + Pergularia daemia (200mg/kg/p.o) 
(EV+GS+PD) 
Estradiol Valerate (4mg/kg) was administered in all group of animal except 
Normal control. Normal control was receives o.4 ml of sesam oil on first day. 
After inducing at 60th days the vaginal smear were taken and conform the 
menstrual irregularity of the animals and serum blood glucose level was 
measured to monitor the insulin resistance. After conformation of PCOS the 
treatment was started with Gymnema sylvestre (400mg/kg), Pergularia daemia 
(200mg/kg) and combination [G.D (400mg/kg) +P.D (200 mg/kg)] for 14th day. 
6.3. Induction of Polycystic Ovary Syndrome in rats 
 
Induction of PCOS in the rats was carried out by administration of Estradiol 
Valerate Intraperitonial route at the dose of 4mg/kg for single dose [63]. 
6.4. Physical Evaluation 
 
6.4.1. Measurement of Body weight 
 
Body weight of each rats in all groups were measured weekly till end of the 
treatment using a weighing balance and the changes were recorded. 
6.4.2. Measurement of Feed Intake 
 
Daily Feed consumption was measured in individual treatment groups by 
using standard weighing balance. 
6.4.3. Examination Vaginal Smear 
 
During a study period the smear was taken from the entire rat. The regularity 
of period was observed the hence under the microscope and photographed [64]. 
6.5. Biochemical Determination 
 
On 74th day of the study, the animals were anesthetized with diethyl ether.  
The blood was drawn through retro orbital plexus and the serum was separated 
after centrifugation of total blood without anticoagulants, at 3000rp, for 10 min. 
The analysis of Blood glucose [65] Total cholesterol, [66]. Triglycerides, [67] serum 
gluctamic-oxaloacetic transaminase (SGOT), serum glutamic pyruvic 
transaminase (SGPT), [68] Alanine aminotransferase (ALT), [69] Urea, Creatinine [70] 
were estimated in serum by standard laboratory technique. 
6.6. Hormonal Determination 
 
The Serum Luteinising hormone (LH), Follicule stimulating hormone (FSH), 
Testosterone Estrogen and Progesterone were measured using an enzyme 
immunoassay kits by standard laboratory techniques [71]. 
6.7. Ultrasound Scan Analysis 
 
At end of the study animal were anesthetizedand placed in ultrasound 
scanner for the scan analysis of the ovary. Scan was taken at the ovary for the 
development of cyst in estradiol induced rats [72]. 
6.8. Measurement of Organs Weight 
 
At the end of study all the animals were sacrificed Liver, kidney, heart, uterus 
and ovary were removed and subjected to gross examination and later weighted. 
6.9. Histopathological Evaluation 
 
Histopathological evaluation was performed the ovaries of control and 
experimental groups were excised immediately after treatment, cleaned from fats 
and weighed. The excised ovaries were fixed in 10% neutral formal saline, 
embedded in paraffin wax, and then sectioned serially at 5-μm thickness. 
Sections were mounted and stained by the haematoxylin and eosin procedure. 
Also some sections were stained by Masson's trichrome (M.T.) and under light 
microscope with 100x magnification for histopathological changes [73]. 
6.10. Statistical analysis 
 
The data represents as mean ± SEM to determine significance and when 
animals were compared over time or within multiple groups, we used one-way 
analysis of variance (ANOVA) followed by post hoc Dunnet’s test by using Graph 
Pad Statistical Package software. The values were considered significant when 
P<0.05. 
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RESULT 
 
7.1. CHANGES IN BODY WEIGHT 
 
The changes in body weight during the trial period was measured, initial 
and final body weight changes in treatment group was compared with control 
group (Group-I) initially there were no significant changes in body weight between 
treatment groups when compare to the control group. On day 74 th final body 
weight of Estradiol Valerate (4mg/kg) treated Group II showed significant increase 
in body weight when compare to other treatment groups (Table 4 & Graph 1). 
7.2. Effect of Gymnema sylvestre, Pergularia daemia and G.sylvestre + 
P.daemia on Feed intake in EV induced PCOS rats. 
Table 5 & Graph 2 illustrated that effect of G.sylvestre, P.daemia and 
G.sylvestre + P.daemia on feed intake in EV induced rats, there is no significant 
different in feed intake between the treatment groups when compared to the 
Vehicle control group (Group-I). Only in Group-II shows little decrease in feed 
intake. 
7.3. Effect of Gymnema sylvestre, Pergularia daemia and G.sylvestre + 
P.daemia on Menstural changes in EV induced PCOS rats. 
On 60th day irregularity of menstrual cycle observed in PCOS induced rats 
as respect from first day. After the 14 days of treatment of P.daemia and 
combination (G.sylvestre+P.daemia) regulate the irregularity of menstrual cycle. 
Fig No. 10 Represent pictures from methylene blue stained samples from 
vaginal smear at different phase of the estrous cycle. At diestrus, only leukocytes 
can be observed, accompanied by few epithelial nucleated cells. At proestrus, 
mostly nucleated and few cornified cells are present along with some leukocytes. 
In estrus (at receptivity), only cornified cells are present. At metestrus, cornified 
epithelial cells and leukocytes are present. 
7.4. Effect of Gymnema sylvestre, Pergularia daemia and 
 
G.sylvestre+P.daemia on Blood glucose in EV induced PCOS rats. 
 
The blood glucose level was no changes on first day in all groups. At day 
 
60 significantly (P<0.001) increase in blood glucose EV induce PCOS group 
compare to the Normal control. At 74th the blood glucose level was significant 
(P<0.001) increase in Group-II compare the Normal control and significantly 
(P<0.001) decrease in treatment groups as compare to the Normal control. As 
compare to individual treatment G.Sylvestre, P.daemia combination possesses 
more significant decrease in Blood glucose level. (Table 6 &Graph 3) 
7.5. Effect of Gymnema sylvestre, Pergularia daemia and 
 
G.sylvestre+P.daemia on Biochemical Parameters in EV induced PCOS rats. 
 
Total cholesterol & triglycerides was significantly (P<0.001) increase in 
PCOS control when compare to the Normal control & G.sylvestre, P.daemia & 
combination (GS+PD) treated group shows significant (P<0.001) decrease in 
Total cholesterol & Triglycerides level. (Table.7) Graph.4&5) 
The SGOT level was significantly (P<0.001) increased in Group-II, more 
significant (P<0.001) decrease in Group-III, Group-IV and Group-V as compare to 
the Normal control. SGPT level was significantly (P<0.05) increase in Group-II as 
compare to the Normal control. G.sylvestre, P.daemia & G.sylvestre + P.daemia 
combination were siginificantly (P<0.05) increase as compare to the Normal 
control. EV group have more significant (P<0.001) as compare to the Normal 
control. G.sylvestre, P.daemia and Combinations shows significant (P<0.001)) 
increased in ALP as compare to the Normal control. Serum Urea, Creatinine level 
was significantly (P<0.001) & (P<0.05) increased as compare to the  control 
group. (Table.8&9) Graph.6-10) 
7.6. Effect of Gymnema sylvestre, Pergularia daemia and 
 
G.sylvestre+P.daemia on Hormonal changes in EV induced PCOS rats. 
 
Table 10 represent the hormonal changes level in PCOS induced rats .LH, 
Testosterone, Estrogen were increased significantly (P<0.001) in PCOS control 
with concominant decreases (P<0.001) in FSH, Progesterone level. These 
changes were reverted to near normal level in all treatment groups. (Graph 11- 
15) 
7.7. Ultrasound Scan Analysis 
 
Fig No: 11 a) shows no changes in ovary in Normal control. Fig No.11 b) 
shows PCOS control with increases number of follicles and cysts. Fig No.11 c) 
Treatment of G.sylvestre shows decrease amount of cyst formation with normal 
growth of follicles. Fig No.11 d) P.daemia treatment shows the normal follicular 
developments Fig No: 11 e) Combination treatments shows no evidence of 
PCOS. 
7.8. Measurement of Organs Weight 
 
The weight of liver & Ovary significantly (P<0.05) increase in the PCOS 
control as compare to the normal control. Group-III, IV&V showed significantly 
decrease in liver & Ovary weight. The group III, IV & V showed greater reduction 
in the ovary and liver weight as compare to the PCOS control. But no significant 
changes in kidney, Uterus and heart in the entire treatment group as compare to 
the normal control. 
7.9. Histopathological Examinations 
 
Histopathological examination of ovary section of normal control (Fig  
No.12 a) showed no histopathological structure alteration of ovary. Micrograph of 
ovary section of Estradiol induced PCOS group showed number of polycyst and 
follicular development with theca lutein cells (Fig No.12 b). The G.Sylvestre 
treatment group showed the minimum number of follicule with saccular dilation 
increased (Fig No.12 c). The P.daemia treatment group showed the granulose 
cells proliferated with follicles (Fig No.12 d). The micrograph of combination 
treatment with Combination shows no evidence of histological alteration in ovary 
(Fig No.11 e) 
Table No.3: Changes in Body weight 
 
Treatment Initial body weight (g) Final body weight (g) 
Group I 
( Vehicle Control) 
165.5±11.03 233.3±16.26 
Group II 
(Estradiol Valerate) 
175.3±12.07 349.7±14.73 a*** 
Group III 
(EV+G.sylvestre) 
166.8±11.16 225.0±10.57 b*** 
Group IV 
(EV+P.daemia) 
168.3±8.72 251.7±6.54 b*** 
Group V 
(EV+G.S+P.D) 
175.7±10.07 228.3±15.79 b*** 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a- Group I vs II, III and. b- Group II vs I, III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.1: Effect of Gymenma sylvestre and Pergularia daemia changes on 
bodyweight in EV induced PCOS rat 
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Table.4: Effect of Gymenma sylvestre and Pergularia daemia on feed intake 
in EV induced PCOS rat 
 
 
Treatment 
Initial feed intake 
(g) 
Final feed intake 
(g) 
Group I 
( Vehicle Control) 
45 70 
Group II 
(Estradiol Valerate) 
43 50 
Group III 
(EV+G.sylvestre) 
45 70 
Group IV 
(EV+P.daemia) 
50 60 
Group V 
(EV+G.S+P.D) 
44 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 2: Effect of Gymenma sylvestre and Pergularia daemia on feed 
intake in EV induced PCOS rat 
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Figure No.10: Vaginal smear of Normal estrus stages 
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Table No.5: Effect of Gymenma sylvestre and Pergularia daemia on Blood 
glucose level in EV induced PCOS rat 
 
 
Treatment 
 
Day-0 
 
Day-60 
 
Day-74 
Group I 
( Vehicle Control) 
88.17±10.12 97.31±11.15 111.5±11.86 
Group II 
(Estradiol Valerate) 
88.94±11.71 221.7±36.81a** 227.7±23.05 a*** 
Group III 
(EV+G.sylvestre) 
91.82±10.07 228.7±28.42a** 105.1±13.87 b*** 
Group IV 
(EV+P.daemia) 
89.49±13.19 200.7±15.55a* 98.42±22.63 b*** 
Group V 
(EV+G.S+P.D) 
100.9±14.85 227.5±32.29a** 83.35±11.44b*** 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a-Group I vs II, III,IV,Vand. b- Group II vs III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.3: Effect of Gymenma sylvestre and Pergularia daemia on Blood 
glucose level in EV induced PCOS rat 
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Table No.6: Effect of Gymenma sylvestre and Pergularia daemia on Total 
cholesterol and Triglycerides in EV induced PCOS rat 
 
 
Treatment 
 
Total cholesterol 
(mg/dl) 
 
Triglycerides 
(mg/dl) 
Group I 
( Vehicle Control) 
86.67±13.88 75.18±11.99 
Group II 
(Estradiol Valerate) 
219.2±21.03 a*** 163.8±14.00 a*** 
Group III 
(EV+G.sylvestre) 
93.50±12.34b*** 71.35±11.22 b*** 
Group IV 
(EV+P.daemia) 
103.3±12.56 b*** 76.67±13.08 b*** 
Group V 
(EV+G.S+P.D) 
86.83±16.49 b*** 69.33±9.25 b*** 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a- Group I vs II, III, IV, V and. b- Group II vs III, IV, V 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
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Graph.4: Effect of Gymenma sylvestre and Pergularia daemia on Total 
cholesterol in EV induced PCOS rat 
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Graph.5: Effect of Gymenma sylvestre and Pergularia daemia on 
Triglycerides in EV induced PCOS rat 
Table No.7: Effect of Gymenma sylvestre and Pergularia daemia on SGOT, 
SGPT and ALP in EV induced PCOS rat 
 
Treatment SGOT SGPT ALP 
Group I 
( Vehicle Control) 
23.6±3.57 34.80±5.67 70.00±9.66 
Group II 
(Estradiol Valerate) 
55.83±6.88 a*** 55.83±5.21 a* 143.8±16.0 a*** 
Group III 
(EV+G.sylvestre) 
23.17±2.02 b*** 34.67±4.61 b* 70.67±16.02 b*** 
Group IV 
(EV+P.daemia) 
24.17±2.30 b*** 34.50±2.18 b* 71.83±12.02 b*** 
Group V 
(EV+G.S+P.D) 
21.50±2.89 b*** 32.17±2.24 b* 67.50±7.39 b*** 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a-Group I vs II, III, IV, V and. b- Group II vs III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
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Graph.6: Effect of Gymenma sylvestre and Pergularia daemia on SGOT in 
EV induced PCOS rat 
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Graph.7: Effect of Gymenma sylvestre and Pergularia daemia on SGPT in 
EV induced PCOS rat 
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Graph.8: Effect of Gymenma sylvestre and Pergularia daemia on ALP in EV 
induced PCOS rat 
Table No.8: Effect of Gymenma sylvestre and Pergularia daemia on Urea 
and Creatinine in EV induced PCOS rat 
 
Treatment Urea (mg/dl) 
Creatinine (mg/dl) 
Group I 
( Vehicle Control) 
8.16±1.10 0.45±0.15 
Group II 
(Estradiol Valerate) 
18.50± 2.74 a** 1.30±0.09 a*** 
Group III 
(EV+G.sylvestre) 
8.66±1.38 a** 0.46±0.13 b*** 
Group IV 
(EV+P.daemia) 
9.00±1.41 a** 0.48±0.08 b*** 
Group V 
(EV+G.S+P.D) 
8.23±0.44 a** 0.43±0.01 b*** 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a-Group I vs II, III ,IV, V and. b- Group II vs III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
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Graph.9: Effect of Gymenma sylvestre and Pergularia daemia on Urea in EV 
induced PCOS rat 
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Graph.10: Effect of Gymenma sylvestre and Pergularia daemia on 
Creatinine in EV induced PCOS rat 
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Table No.9: Effect of Gymnme sylvestre and pergularia daemia on Hormonal 
determination in EV induced PCOS rat 
 
 
Treatment 
LH 
(ng/dl) 
FSH 
(ng/dl) 
Estrogen 
(ng/dl) 
Testosterone 
(ng/dl) 
Progesterone 
(ng/dl) 
Group I 
( Vehicle 
Control) 
1.78±0.06 5.65±1.78 7.50±0.56 36.67±2.10 0.66±0.04 
Group II 
Estradiol 
Valerate 
5.16±0.09 
a *** 
2.66±0.20 
a*** 
23.83±1.70 
a*** 
103.3±13.08 
a*** 
0.18± 0.03 
a*** 
Group III 
(EV+G.sylvestre 
) 
1.68±0.02 
b *** 
7.98±0.14 
a** b*** 
4.90±0.28 
b*** 
52.83±1.701 
b*** 
0.66±0.08 
b*** 
Group IV 
(EV+P.daemia) 
1.73±0.05 
b*** 
8.85±1.01 
a*** b*** 
6.70±0.88 
b*** 
42.67±2.04 
b*** 
0.73±0.07 
b*** 
Group V 
(EV+G.S+P.D) 
1.03±1.30 
a** b*** 
7.43±0.13 
a* b*** 
8.31±0.37 
b*** 
22.17±1.42 
b*** 
0.71±0.05 
b*** 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a-Group I vs II, III,IV,V and. b- Group II vs III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
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Graph.11: Effect of Gymenma sylvestre and Pergularia daemia on 
Leutinizing Hormone (LH) in EV induced PCOS rat 
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Graph.12: Effect of Gymenma sylvestre and Pergularia daemia on Follicular 
stimulating Hormone (FSH) in EV induced PCOS rat 
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Graph.13: Effect of Gymenma sylvestre and Pergularia daemia on Estrogen 
in EV induced PCOS rat 
 
 
150 
 
 
 
100 
 
 
 
50 
 
 
 
0 
 
 
 
 
 
Graph.14: Effect of Gymenma sylvestre and Pergularia daemia on 
Testosterone in EV induced PCOS rat 
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Graph.15: Effect of Gymenma sylvestre and Pergularia daemia on 
Progesterone in EV induced PCOS rat 
Table No.10: Changes in Liver & Ovary weight 
 
 
 
Treatment 
Liver weight 
(g/100g body weight 
Ovary weight 
(g/100g body weight) 
Group I 
( Vehicle Control) 
5.11±0.18 0.34±0.14 
Group II 
(Estradiol Valerate) 
6.51±0.24 1.06±0.33 a* 
Group III 
(EV+G.sylvestre) 
6.29±0.12 0.45±0.16 
Group IV 
(EV+P.daemia) 
6.32±0.14 0.37±0.05 
Group V 
(EV+G.S+P.D) 
6.29±0.14 0.35±0.08 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a-Group I vs II, III,IV,V and. b- Group II vs III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05 
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Graph.16: Changes in Liver Weight 
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Graph.17: Changes in Ovary Weight 
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Table.11: Changes in kidney, Uterus and Heart weight 
 
 
Treatment 
Kidney weight 
(g/100g body 
weight 
Uterus weight 
(g/100g body 
weight) 
Heart weight 
(g/100g body 
weight 
Group I 
( Vehicle Control) 
1.50±0.01 1.36±0.09 0.59±0.20 
Group II 
(Estradiol Valerate) 
1.61±0.18 a* 1.46±0.15 0.66±0.18 
Group III 
(EV+G.sylvestre) 
1.64±0.17 1.39±0.11 0.67±0.08 
Group IV 
(EV+P.daemia) 
1.58±0.17 1.40±0.04 0.64±0.13 
Group V 
(EV+G.S+P.D) 
1.49±0.10 b* 1.32±0.01 0.62±0.11 
 
Values are expressed as mean ± SEM, n-6. Comparisons were made between: 
a-Group I vs II, III,IV,V and. b- Group II vs III, IV, V. 
Symbols represent statistical significance: ***P<0.001, **-P<0.01, *-P<0.05. 
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Graph No.18: Changes in Kidney weight 
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Graph No.19: Changes in Uterus weight 
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Graph No.20: Changes in Heart weight 
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Fig no: 11 Ultrasonic scan analysis for EV induce PCOS rat. 
 
a)  Group-I Normal Control b) Group-II PCOS control 
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c) Group-III G. sylvestre d) Group-IV P. daemia 
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Fig No: 11 Histopathology changes for estradiol valerate induced PCOS in 
rat Ovary. 
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Polycystic ovary syndrome is a common endocrine disorder affecting 4- 
12% of women in their reproductive age. [74] PCOS is frequently associated with 
anovulation and infertility. Due to anovulation, 75% of women are affected by 
infertility. In that among PCOS women 47% are affecting by oligomenorrh.[84] In 
PCOS women, clinically characterized by hyperinsulinaemia, hyper androgenism, 
obesity and enlarged ovaries with small multiple cysts leads to anovulation and 
pregnancy complications. 
In this study polycystic ovary syndrome was induced by the administration 
of Estradiol Valerate 4mg/kg at a single dose. Exposure to a single dose of EV in 
adult rat cause irregular estrus cycles, lack of ovulation and excessive amount of 
follicular development and irregular estrus cycle75. Results of this study conform 
the administration of EV 4 mg/kg produce the PCOS in rats. 
Body weight was significant increased in EV induced PCOS group as 
compare to the control group. It might be due to a high incidence of 
atretic/degenerative secondary follicles and the ovaries in EV induced rats. The 
structural changes included an increase in the volume of the Ovary, Cortex, Cysts 
and Corpus luteum76. In treatment groups there were no significant change in 
body weight as compare to the normal control. 
The effect of feed intake in EV induced PCOS rats, there is no significant 
different in feed intake between the treatment groups when compared to the 
Vehicle control group. Only Group-II shows little decrease in feed intake. 
The irregularity of estrus cycle was examined in PCOS rats by examine the 
Vaginal smear. EV induces PCOS animal’s shows irregularity of estrus cycle due 
to direct effect of hormonal secretions to increases the LH level and decrease the 
FSH level and also decrease production of progesterone. Progesterone is the 
main hormones of the menstrual cycle, Hyperandrogenimia, abnormal follicular 
development and anovulation. [77] Treatment groups of Gymnema sylvestre, 
Pergularia daemia and combination of (G.D+P.D) (III, IV&V) significantly restored 
the estrus cycle in PCOS induces rats as compare to PCOS control group. This 
revealed that treatment of Gymnema sylvestre and Pergularia daemia are more 
effective in correction of menstrual irregularity and abnormal follicular 
development. 
Blood glucose level in EV induced PCOS rats showed significant increase 
the blood glucose. It conform the administration of EV increase the androgen 
production and insulin resistants leads to hyperinsulinamia. [78] Gymnema 
sylvestre, Pergularia daemia treatment groups were significantly decreased the 
blood glucose. The effect of Gymnema sylvestre plant powder alone shows 
glucose utilization in insulin sensitive tissue by reducing the hyperinsulinamia [79] 
and the Pergularia daemia plant powder treatment reduce the Blood Glucose 
level by stimulation of the residual pancreatic mechanism or to a probable 
increase in the peripheral utilization of glucose and the combination of G.D+P.D 
more significant decrease in blood glucose when compare to the PCOS control 
group. [80] In comparison between treatment groups combination possess 
profound reduced effect on the blood glucose level. 
In present study, Total cholesterol and Triglycerides level in EV induce 
PCOS rats were significant increase as compare to the Gymnema sylvestre, 
Pergularia daemia and its combinations (G.D+P.D) treatment groups (III, IV&V). 
The EV induce PCOS rat has high lipid and cholesterol content. It might be 
causes of obesity and atheroschelorsis. [81] The Gymnema sylvestre and 
Pergularia daemia treatment showed significant decrease the Total cholesterol 
and Triglycerides. In comparison between the treatment groups combination 
posses more reduction effect on Total cholesterol and Triglycerides. 
In this study, SGOT, SGPT and ALP level was significantly increased in 
PCOS control group as compared to the normal control. It indicate that the 
impairment of hepatic function in PCOS group. The elevated level of SGOT, 
SGPT and ALP was significantly reverted in all the treatments. Improvement of 
hepatic function may raise the serum SHBG enzyme level which reduces the 
bioavailability of sex hormones82. 
 
The increased serum urea and creatinine level in PCOS rat it might be the 
causes of renal dysfunction the earliest stages of atherogenesis is endothelial cell 
dysfunction. [83] In additional increased serum creatinine level was found in EV 
induced PCOS rats, which shows the kidney dysfunction in PCOS rats. 
Alterations were observed in PCOS condition were normalised and greater effect 
in all the treatment groups. Result of this study suggests the Gymnema sylvestre 
and Pergularia daemia treatment prevent the impairment of renal functions 
evident by a decrease in serum urea and creatinine. [84] 
 
According to the hormonal determination EV induce PCOS rats shown 
significant increase in serum LSH, Estrogen, Testosterone and decrease in FSH 
and Progesterone compare to control group. 
Estrodiol Valerate administration increased sensitivity of the pituitary to 
GnRH result in increase in leutinizing hormone (LH) and increased insulin levels 
mainly amplify the intrinsic abnormality of their steroidogenesis. Excess androgen 
activity leads to hyperandrogenism. By administration of Gymnema sylvestre 
reduce the insulin secretion [85] and degenerations of the follicular cells in ovaries 
as well as elevated LH level in Pergularia daemia treatment 86. In comparison 
between the treatment groups combination treatment posses most decrease in 
LH level. 
In present study there was significant decrease in FSH level in PCOS rats. 
EV treatment animals increased the sensitivity of the pituitary to GnRH results in 
FSH suppression it may responsible for the maintenance of the cystic 
development of the ovaries. In presence study individual and combination 
treatment of Gymenema sylvestre and Pergularia daemia allows the new follicular 
development, maturity of follicules and correction of irregularity of estrus cylce 
occur as compare to the PCOS control by significant increase in FSH 87. The level 
of FSH was higher in Pergularia daemia treated group as compare to the other 
treatments. 
In PCOS condition significantly increases in Estrogen level. Estradiol 
valerate administration causes alter the level of estrogens leads to the formation 
of cysts in the ovary and development of follicles88. In this study showed that EV 
induced PCOS rats are increases in serum estrogen. Gymenema sylvestre and 
Pergularia daemia treatment significantly decreases in estrogen level compared 
to the PCOS group. This implying caused to improvement in endocrine function 
and recovery of ovulatory functions. 
In non steroidal aromatase inhibitors (EV) administration of PCOS rat 
shows excess amount of androgen and causes the anovulation. In this present 
study by administration of Gymenema sylvestre to drastically decreased 
testosterone and regulates the process of ovulation Pergularia daemia shows 
more significant in the testosterone with regulate anovulation and combinations of 
 
G.D+P.D to significant decrease as compare to the Normal control. [89] 
 
Progesterone was significant decrease in PCOS rats. Progesterone is 
important hormone for women menstrual cycle, absence or a decrease of 
progesterone ovulation does not occur leads to anovulation [90] Estradiol Valerate 
administration of PCOS rats decreased progesterone production, [91] in present 
study individual & combination treatment of G.sylvestre and P.daemia repair the 
luteal functions & anovulation in EV induce PCOS rats. 
Ultra sound scan changes in EV induced Polycystic ovarian syndrome rats 
are the diagnostic ovary measures which indicating the follicular cyst  
development due to hyperandrogenism. In this study USS confirm the PCOS 
control animals with develop polycyst. Gymnema sylvestre and Pergularia daemia 
treated groups showed normal ovary with mild evidence of cyst development due 
to the number of granulose cell layers increased and follicular fluid was orderly 
arranged. Additionaly, theca cell layer become thinner while the number of 
corpora lutea increase and dialted follicles. [92] In comparison between treatment 
group G.sylvestre+P.daemia treated group showed more effective compare with 
very mild incidence of cyst as compare to the PCOS control. 
The increase in liver and ovary weight are related to inhibit the hepatic 
synthesis effect of SHBG reduction, and increases the immature development of 
follicles in ovary and increase androgen secretions in EV induced PCOS rat. All 
the treatment groups indicate reduction in the weight of these organs, which are 
related to the endocrine functions. [93] It can be effective action for the G.sylvestre 
and P.daemia. When comparison between these treatments groups 
G.sylvestre+P.daemia combination treated group have more effective action on 
these organs. 
Histopathological study of PCOS control showed more number of 
developed cyst and theca lutein cells. G.sylvestre and P.daemia showed fewer 
developed cysts. In comparison combination G.sylvestre+P.daemia have no 
incidence of follicular cysts. 
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SUMMARY AND CONCLUSION 
 
In this study PCOS was induced by administration of Estradiol Valerate. It 
conforms the elevated level of Blood glucose, total cholesterol, triglycerides and 
hormonal changes like increase in the level of LH, Testosterone, Estrogen, 
decreases the FSH and Progesterone with menstrual irregularity, confirmed by 
ultrasound analysis and histopathological changes in the ovary of PCOS control. 
The treatment of G.sylvestre shows significant reduction effect in blood 
glucose level, Total cholesterol and Testosteone have a most prominant action it 
might be due to the presence of phytoconstituents like Gymnemic acid, 
glycosides, saponins. 
P.daemia shows the most significant increased effect on the FSH and 
Progesterone it may be due to the presence of Pituitrin, alkalodids, triterpenes, 
saponins, and steroidal compounds. 
It might be concluded the individual administraton of G.sylvestre reduce  
the insulin resistance, decrease androgen production and P.daemia have 
profound beneficial effect on anovulation, menstrual irregularity. But the 
combination G.sylvestre+P.daemia had shown the synergistic activity to correct 
the hyperinsulinemia, anovuation and hyperandrogenism. 
Further Isolation of active constituents and scope full clinical studies data 
are needed to initiate these combination for the better treatment and management 
of PCOS. 
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